Pharmaceutical News and Articles
Print Email

Sepragen Announces the Completion of Cyto Biologic Technologies Acquisition

HAYWARD, Calif.--(BUSINESS WIRE)--Dec 6, 2007 - Sepragen Corporation (Pink Sheets:SPGNA), a provider of patented technology and equipment for bio-processing needs in the biotech industry, today announced that it has completed the acquisition of Cyto Biologic Technologies, Inc. Terms of the acquisition were not disclosed. Of the acquisition, Vinit Saxena, CEO of Sepragen, stated, "The consummation of the acquisition of Cyto Biologic Technologies allows Sepragen to provide our bio-processing customers with an innovative technology to rapidly grow cells to high densities with resultant higher productivity." Saxena continued, "What is most significant is that this is the first step in transforming Sepragen from being a supplier of individual tools to becoming a value-added solution provider in the bio-processing space. Cells grown on the bioreactor produce biological molecules, which can be further processed by several technologies, including Sepragen columns, resins and QuantaSep systems."

Sepragen has already leased additional facility space and is expanding its laboratory and production capabilities to meet the anticipated need resulting from the bioreactor, which has hitherto been in beta testing and for which Sepragen has already received its initial order from BD. "We are very happy with results from beta test sites and the interest seems very promising," Saxena concluded.

Sepragen Corporation markets innovative bio-processing equipment that biotechnology companies use to develop and manufacture high value diagnostics as well as therapeutic drugs. Sepragen has a number of customers for its current products that are industry leaders and approximately two dozen approved drugs are made using Sepragen Products.

The statements in this release that relate to future events or performance, statements about growth, market acceptance, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for the commercial acceptance of the Company's products and services, the availability of components, competitors' product introductions and other risks identified in the Company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Contact

Sepragen Corporation
Vinit Saxena, CEO, 510-475-0650 ext. 23
vsaxena@sepragen.com

Latest Pharma Industry News...

Pharma Industry News Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources

Daily MedNews
Pharma Industry News
New Drug Applications
New Drug Approvals
Clinical Trial Results
Generic Drug Approvals
Monthly Update Archive

Services
Home
A to Z Drug List
Drugs by Condition
Drug Side Effects
Natural Products
Community Forums
Interactive Tools
Pill Identifier
Interactions Checker
MedNotes beta
Support Groups beta
Drug Image Search
Phonetic Search
News & Articles
Latest Drug News
FDA Drug Alerts
New Drug Approvals
New Drug Applications
Clinical Trial Results
Medical Encyclopedia
News FeedsRSS Feeds
Health Professionals
Professional Resources
Drugs by Classification
Patient Care Notes
Drug Imprint Codes
Medical Dictionary
Animal Medicine
Veterinary Drugs
Advertise Here
Recent Searches
Tamiflu
Phentermine
Kinrix
Relafen
Xifaxan
Natrecor
Mozobil
Cellcept
Mesothelioma
Vimpat
Adacel
Motrin
Propecia
Xenical
Human Secretin
Antivert
Methylprednisolone
Toradol
Oraqix
Advair
Coartem
Denavir
Lithium
Leukine
Fazaclo
Recently Approved
Lysteda
Istodax
Pennsaid
Arzerra
Votrient
Twynsta
Cervarix
Berinert
Stelara
Folotyn
More...

Subscribe to our popular newsletter containing a regular roundup of medication news, alerts and new drug approvals.


MedNotes
Most Popular Internet Searches
Lipitor
Viagra
Zoloft
Crestor
 Cialis
Wellbutrin
Effexor
Celebrex
 Levitra
Neurontin
Paxil
Zocor
Latest FDA Drug Alerts
RSS
Get alerts delivered by email
Meridia (sibutramine hydrochloride): Early Communication about an Ongoing Safety Review
November 20, 2009
FDA notified healthcare professionals and patients that it is reviewing preliminary data from a recent study suggesting that...
Vicks Sinex Nasal Spray - Recall
November 19, 2009
Procter & Gamble and FDA notified consumers of a voluntary recall of three lots of Vicks Sinex Nasal Spray in the United...
RockHard Weekend - product contains undeclared drug ingredient
November 18, 2009
RockHard Laboratories and FDA notified consumers that RockHard Weekend, a product sold as a dietary supplement, contains...
Clopidogrel (marketed as Plavix) and Omeprazole (marketed as Prilosec) - Drug Interaction
November 17, 2009
FDA notified healthcare professionals of new safety information concerning an interaction between clopidogrel (Plavix), an...
More...
Advertisement
Latest Drug Information Updates

Lysteda
Lysteda (tranexamic acid) is an antifibrinolytic agent for the treatment of women with menorrhagia, heavy menstrual bleeding (HMB), and its accompanying symptoms.

Pennsaid
Pennsaid is a topical non-steroidal anti-inflammatory drug (NSAID) used for the treatment of signs and symptoms of osteoarthritis of the knee.

Istodax
Istodax (romidepsin) a histone deacetylase (HDAC) inhibitor indicated the treatment of cutaneous T-cell lymphoma.

Cervarix
Cervarix (human papillomavirus bivalent (types 16 and 18) is a is a preventative cervical cancer vaccine for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 in girls and young women (aged 10-25).

Votrient
Votrient (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma.

Arzerra
Arzerra (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia.

Twynsta
Twynsta (telmisartan/amlodipine) is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel blocker (DHP-CCB) combination product indicated for the treatment of hypertension alone or with other antihypertensive agents.

Berinert
Berinert (C1-esterase inhibitor (human)) is a plasma derived C1 Esterase Inhibitor indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients.

Stelara
Stelara (ustekinumab) is a human monoclonal antibody for the treatment of moderate to severe plaque psoriasis.

Influenza A (H1N1) 2009 Monovalent Vaccine
Influenza A (H1N1) 2009 Monovalent Vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons ages 18 years of age and older against influenza disease caused by pandemic (H1N1) 2009 virus.

Zirgan
Zirgan (ganciclovir ophthalmic gel) is a topical ophthalmic antiviral preparation for the treatment of acute herpetic keratitis (dendritic ulcers).

Vibativ
Vibativ (telavancin) is a bactericidal, once-daily injectable antibiotic for the treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

Folotyn
Folotyn (pralatrexate) is a folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Valturna
Valturna is a combination of aliskiren (a direct renin inhibitor) and valsartan (an angiotensin II receptor blocker) indicated for the treatment of high blood pressure.

Bepreve
Bepreve (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis.

More...

(web4)